The rapid rate of breakthroughs in immuno-oncology (IO) continues to disrupt diagnostic processes and workflows in cancer care. As more patients with different types of cancers are treated with immune checkpoint inhibitor therapy, pathologists and laboratory professionals need to work closely with oncologists and other cancer clinicians to optimize IO biomarker testing and ensure that patients are treated with the right agents.
This live 1.5-hour CME multidisciplinary panel discussion will review the evolving landscape of IO biomarker testing and highlight practical examples of quality improvements that can be implemented in cancer centers. This practical discussion will include multidisciplinary perspectives around IO biomarker testing, the role of standardized processes and protocols, and the need to continuously evaluate and apply the latest evidence when diagnosing cancer and treating patients with immune checkpoint inhibitor therapy.
Learning Objectives:
-
Review recent clinical evidence around immuno-oncology (IO) biomarker testing and the use of immune checkpoint inhibitor therapy
-
Outline pathology-driven processes that can improve IO biomarker testing
-
Describe how members of the multidisciplinary cancer care team can implement new processes to improve the care of patients treated with immune checkpoint inhibitor therapy
-
List specific examples of quality improvements directed around the use of IO biomarkers and immune checkpoint inhibitor therapy
Faculty:
Joseph Kim, MD, MPH, MBA
Q-Synthesis, LLC
Langhorne, PA
Mamatha Chivukula, MD, FASCP
Director, Immunohistochemistry
Sutter Health
San Francisco, CA
Tori McCurdy, FNP, OCN
Lead Nurse Practitioner
Baptist Cancer Center, Baptist Medical Group
Memphis, TN
Alejandro R. Zuretti, MD, FASCP, FCAP
Medical Director of Laboratories
Maimonides Medical Center
Brooklyn, NY
The American Society for Clinical Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
The ASCP designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
These activities also meet Continuing Certification (CC) Part II Lifelong Learning and Self-Assessment Module (SAMs CME) requirements.
ASCP designates these enduring materials for a maximum of 1.5 CMLE credit. These activities meet CMP and state re-licensure requirements for laboratory personnel.
For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, during normal business hours: Monday through Friday, 8 a.m. to 6 p.m. Eastern Time
Method of Participation
To complete the activity and receive credit, the participant must complete the online course. CME certificates will be provided on-line.
Funded by an independent educational grant from Pfizer/Merck KGaA